Medisun Medical Investment in Cell Production Method has obtained US patent
Celyad acquires the first US patent for the production of TCR-deficient CAR-T cells from allogeneic origin
Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris and NASDAQ: CVAD), a leader in the development industry in the engineering cell therapy and the main focus is on cardiovascular disease and tumor immunity. Announced the acquisition of a US Patent grant No. 9273283. The patent is a method for the production of human primary T cells derived from an allogeneic origin, which is modified to be a lack of T cell receptor (TCR) and a chimeric antigen receptor (CAR).
US Patent No. 9273283 is the second in the list of Celyad alliteration intellectual property patents granted by the US Patent and Trademark Office (USPTO). The first US patent (9181527) – granted in December 2015 to Celyad – is also related to TCR deletion of CAR – T cells, but not specific to its production methods. This new patent adds a more comprehensive approach to the production of these modified allogeneic T cells and provides them as a drug. This strengthens Celyad’s patent coverage for CAR T cells. These products may help patients with various types of diseases, especially cancer patients. Celyad confirmed its leadership in engineering cell therapy and allogeneic CART through this strengthening of the patent portfolio in the CAR – T field. Since it does not depend on the patient’s own cells, allogeneic technology has the potential to expand the treatment of CAR T cell immunotherapy.
“We are pleased to receive this new patent,” said Dr. Christian Homsy, Chief Executive Officer of Celyad. “As far as we know, this is the first production method to cover TCR- deficient CAR –T cells from allogenic sources and use this patent to treat the patient. With this patent and US patent No. 9181527, which was acquired a few months ago, we have a strong patent portfolio that covers key elements of the TCR missing CAR-T cell production value the chain of allogeneic origin, Through strategic cooperation and partnership, we plan to maximize the potential of allogenic CAR T cell platforms in the internal and external potential.”
Dr. Peter De Waele, the Vice President said “The re-acquisition of this patent not only demonstrates the independence of our patients, which supports our commitment to the development of allogeneity in the intellectual property division. It supports our
research and development on the improvement on the processing efficiency and increased the availability
At present, Celyad preclinical research and development of allogeneic cancer treatment is ongoing. The study used a TCR inhibitory molecule, or “TIMTM” to bind to a next- generation CAR construct containing a Natural Killer Cell receptor, or “NKR”. This proprietary process forms a TCR-deficient NKR T cell, which is designed to not causing or substantially reduce the graft versus host reaction (GVHD).